127 related articles for article (PubMed ID: 3472677)
1. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.
Borsi JD; Revesz T; Schuler D
Cancer Chemother Pharmacol; 1987; 19(3):261-4. PubMed ID: 3472677
[TBL] [Abstract][Full Text] [Related]
2. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Cancer; 1987 Dec; 60(12):3020-4. PubMed ID: 3479231
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
Borsi JD; Moe PJ
Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.
Evans WE; Crom WR; Stewart CF; Bowman WP; Chen CH; Abromowitch M; Simone JV
Lancet; 1984 Feb; 1(8373):359-62. PubMed ID: 6141424
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate absorption in children with acute lymphoblastic leukemia.
Craft AW; Rankin A; Aherne W
Cancer Treat Rep; 1981; 65 Suppl 1():77-81. PubMed ID: 6948609
[TBL] [Abstract][Full Text] [Related]
6. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Moe PJ
Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic significance of systemic clearance of methotrexate in acute lymphoid leukemia in childhood].
Borsi J; Révész T; Schuler D
Orv Hetil; 1986 Feb; 127(8):439-42. PubMed ID: 3456552
[No Abstract] [Full Text] [Related]
9. Modification of oral methotrexate absorption in children with leukemia.
Mahony MJ; Murphy MS; Wadsworth J; Mott MG
Cancer Chemother Pharmacol; 1984; 12(2):131-3. PubMed ID: 6583027
[TBL] [Abstract][Full Text] [Related]
10. The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses.
Green DM; Brecher ML; Blumenson LE; Grossi M; Freeman AI
Cancer; 1982 Dec; 50(12):2722-7. PubMed ID: 6958351
[TBL] [Abstract][Full Text] [Related]
11. The treatment of primary childhood acute lymphocytic leukemia with intermediate dose methotrexate.
Sinks LF; Wang JJ; Freeman AI
Haematol Blood Transfus; 1981; 26():99-107. PubMed ID: 6947942
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia.
Sackmann-Muriel F; Svarch E; Eppinger-Helft M; Braier JL; Pavlovsky S; Guman L; Vergara B; Ponzinibbio C; Failace R; Garay GE; Bugnard E; Ojeda FG; De Bellis R; de Sijvarger SR; Saslavsky J
Cancer; 1978 Oct; 42(4):1730-40. PubMed ID: 101296
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute lymphoblastic leukemia in children. Long-term results of two trials.
Cáp J; Koza I; Misíková Z; Foltinová A; Strbáková E
Neoplasma; 1983; 30(1):81-92. PubMed ID: 6339961
[TBL] [Abstract][Full Text] [Related]
14. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.
Lobel JS; O'Brien RT; McIntosh S; Aspnes GT; Capizzi RL
Cancer; 1979 Mar; 43(3):1089-94. PubMed ID: 284840
[TBL] [Abstract][Full Text] [Related]
16. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
[TBL] [Abstract][Full Text] [Related]
17. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse.
Brecher ML; Weinberg V; Boyett JM; Sinks LF; Jones B; Glicksman A; Holland JF; Freeman AI
Cancer; 1986 Sep; 58(5):1024-8. PubMed ID: 3524797
[TBL] [Abstract][Full Text] [Related]
18. [Acute lymphoblastic leukemia in childhood: the COALL studies].
Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
[TBL] [Abstract][Full Text] [Related]
20. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
